Avacta Group Plc (FRA:RTQ1)
Germany · Delayed Price · Currency is EUR | Market Cap | 340.91M +87.5% |
| Revenue (ttm) | 131.83K -96.0% |
| Net Income | -73.03M |
| EPS | -0.20 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 4,257 |
| Open | 0.7750 |
| Previous Close | 0.7850 |
| Day's Range | 0.7750 - 0.7750 |
| 52-Week Range | 0.2920 - 0.9100 |
| Beta | n/a |
| RSI | 54.26 |
| Earnings Date | Apr 24, 2026 |
About Avacta Group
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that driv... [Read more]
Financial Performance
In 2024, Avacta Group's revenue was 113,000, a decrease of -96.04% compared to the previous year's 2.85 million. Losses were -52.84 million, 58.9% more than in 2023.
Financial numbers in GBP Financial StatementsNews
Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives
AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple ...
Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors
Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life scien...